AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31268132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program
Number of subjects: 60
Study 29236639 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB‐FHbp
Number of subjects: 6896
Study 26910781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-Gentamicin solution (Group 2)
Number of subjects: 80
Study 26910781 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (Group 1)
Number of subjects: 80
Study 24690206 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with dyspareunia
Number of subjects: 38
Study 24690206 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners of women with dyspareunia
Number of subjects: 38
Study 23118072 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT/GISTM (n = 13)
Number of subjects: 36
Study 23118072 — intervention group
Group type: COMPARATOR
Intervention: DBT/GISTM-S (n = 12)
Number of subjects: 36
Study 23118072 — intervention group
Group type: COMPARATOR
Intervention: DBT/C (n = 11)
Number of subjects: 36
Study 19047285 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg on days 1 and 2 with chemotherapy on day 3 (150 PRE)
Number of subjects: 86
Study 19047285 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 1,500 mg on days 1 and 2 with chemotherapy on day 3 (1,500 PRE)
Number of subjects: 86
Study 19047285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy on day 1 with erlotinib 1,500 mg on days 2 and 3 (1,500 POST)
Number of subjects: 86
Study 17606173 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with concurrent economic evaluation
Number of subjects: 12294
Study 17606173 — intervention group
Group type: COMPARATOR
Intervention: Studies without concurrent economic evaluation
Number of subjects: 12294
Study 17606173 — intervention group
Group type: EXPERIMENTAL
Intervention: Between group difference
Number of subjects: 12294
Study 14687093 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sevoflurane
Number of subjects: 0
Study 14687093 — intervention group
Group type: COMPARATOR
Intervention: 8% sevoflurane
Number of subjects: 0
Study 11701073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure sesame oil
Number of subjects: 79
Study 11701073 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (ISCS)
Number of subjects: 79
Study 9073140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal triglyceride infusion under euglycemic conditions
Number of subjects: 10
Study 9073140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal triglyceride infusion under hyperglycemic conditions
Number of subjects: 10
Study 9073140 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hyperglycemia vs euglycemia during intraduodenal triglyceride infusion
Number of subjects: 10
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase (L-ASP) added to consolidation therapy for average risk patients (MRG)
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administered in intervals between intensification elements for high risk patients (HRG)
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial response to a 7-day exposure to prednisone and first intrathecal injection of MTX
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of blasts in the bone marrow (BM) at day 15 of treatment
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocol including 8-drug induction, consolidation, reinduction, and maintenance therapy
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive cranial irradiation (12 Gy) for MRG and HRG patients
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall probability for event-free survival (p-EFS)
Number of subjects: 1468
Study 7526027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 1468
Study 3319643 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin infusion
Number of subjects: 10
Study 3319643 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin infusion
Number of subjects: 10
Study 30025308 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home PMTO
Number of subjects: 918
Study 30025308 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home PMTO (completers)
Number of subjects: 918
Study 30025308 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home PMTO (non-completers)
Number of subjects: 918
Study 30025308 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 918
Study 27238465 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827
Study 27238465 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study 27238465 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 827
Study 26351359 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1123
Study 26351359 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque length
Number of subjects: 1123
Study 23447373 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10mg daily for 3 months)
Number of subjects: 27
Study 23447373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21306238 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg once daily)
Number of subjects: 410
Study 21306238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 19011227 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute lymphatic treatment
Number of subjects: 15
Study 19011227 — intervention group
Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 15
Study 12824973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive/clomiphene citrate
Number of subjects: 48
Study 12824973 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48
Study 9440034 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain (barbell squat)
Number of subjects: 24
Study 9440034 — intervention group
Group type: COMPARATOR
Intervention: Open kinetic chain (knee extension and hip adduction)
Number of subjects: 24
Study 7880697 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 250 micrograms kg‐1
Number of subjects: 54
Study 7880697 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 500 micrograms kg‐1
Number of subjects: 54
Study 1975324 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of hyperosmolar glucose solution
Number of subjects: 31
Study 1975324 — intervention group
Group type: COMPARATOR
Intervention: Local and systemic prostaglandins
Number of subjects: 31
Study 29812 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg)
Number of subjects: 10
Study 29812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorthiazide (50 mg)
Number of subjects: 10
Study 29812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Amiloride and Hydrochlorthiazide (50 + 5 mg)
Number of subjects: 10
Study 29812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30679770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA anodal tDCS of right M1
Number of subjects: 28
Study 30679770 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 28542805 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hydrocortisone (HCT) dose (0.4-0.6 mg/kg body weight)
Number of subjects: 47
Study 28542805 — intervention group
Group type: COMPARATOR
Intervention: Lower hydrocortisone (HCT) dose (0.2-0.3 mg/kg body weight)
Number of subjects: 47
Study 26384721 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by volunteers and community mobilisation events to promote immunisation in intervention group villages.
Number of subjects: 432
Study 26384721 — intervention group
Group type: COMPARATOR
Intervention: Community mobilisation to promote nutrition in control group villages.
Number of subjects: 432
Study 23524089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0 mg, 30 mg, 60 mg, 120 mg)
Number of subjects: 8
Study 23524089 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0 mg, 30 mg, 60 mg, 120 mg)
Number of subjects: 8
Study 23524089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg) with naloxone
Number of subjects: 8
Study 23524089 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (60 mg) with naloxone
Number of subjects: 8
Study 23524089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 8
Study 23524089 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (60 mg)
Number of subjects: 8
Study 21271460 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (n=31)
Number of subjects: 63
Study 21271460 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 63
Study 19592625 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg weekly
Number of subjects: 356
Study 19592625 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg biweekly
Number of subjects: 356
Study 19592625 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 100 mg monthly
Number of subjects: 356
Study 19592625 — intervention group
Group type: COMPARATOR
Intervention: Exenatide (active reference)
Number of subjects: 356
Study 19592625 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg weekly, 50 mg biweekly, 100 mg monthly)
Number of subjects: 356
Study 17010541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 20
Study 17010541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14709461 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior three-in-one femoral (FEM) technique
Number of subjects: 24
Study 14709461 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment (PSOAS) technique
Number of subjects: 24
Study 14709461 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 24
Study 11546900 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallenberg's syndrome (WS) patients
Number of subjects: 20
Study 11546900 — intervention group
Group type: COMPARATOR
Intervention: Patients with unilateral hemispheric stroke
Number of subjects: 20
Study 11546900 — intervention group
Group type: COMPARATOR
Intervention: Patients with unilateral peripheral 9th and 10th cranial nerve palsies
Number of subjects: 20
Study 9766261 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 mcg) administered through continuous subcutaneous night infusion from midnight to 08:00 at increasing rate between 03:00 and 08:00 h
Number of subjects: 8
Study 9766261 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 mcg) administered through subcutaneous injections at 20:00, 22:00, and 24:00 h
Number of subjects: 8
Study 9766261 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 8
Study 7828258 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ephedrine 30 mg, orally, 30 min before subarachnoid block
Number of subjects: 200
Study 7828258 — intervention group
Group type: COMPARATOR
Intervention: Routine premedication only (Control Group)
Number of subjects: 200
Study 3046593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined non‐specific and specific immunotherapy (BCG and neuraminidase‐treated autologous tumour cells) over a 2 year programme
Number of subjects: 301
Study 3046593 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 301
Study 31883728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt load
Number of subjects: 8
Study 30421667 — intervention group
Group type: EXPERIMENTAL
Intervention: CareSTEPS telephone-based intervention for caregivers
Number of subjects: 39
Study 28718223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tät® app for self-management of stress urinary incontinence
Number of subjects: 62
Study 26525620 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day + guanfacine 1 mg/day (N+G)
Number of subjects: 301
Study 26525620 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg/day + guanfacine placebo (N+GP)
Number of subjects: 301
Study 26525620 — intervention group
Group type: COMPARATOR
Intervention: naltrexone placebo + guanfacine (NP+G)
Number of subjects: 301
Study 26525620 — intervention group
Group type: COMPARATOR
Intervention: double placebo (NP+GP)
Number of subjects: 301
Study 23619317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery at the Bariatric and Metabolic Institute Abu Dhabi
Number of subjects: 275
Study 23619317 — intervention group
Group type: COMPARATOR
Intervention: ACS NSQIP hospitals
Number of subjects: 275
Study 22036127 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (α' < 39.5°)
Number of subjects: 362
Study 22036127 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (α' ≥ 39.5°)
Number of subjects: 362
Study 19132200 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 1935
Study 19132200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 1935
Study 19132200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1935
Study 19132200 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis prior to enrollment
Number of subjects: 1935
Study 17357764 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acclimation
Number of subjects: 40
Study 17357764 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive acclimation
Number of subjects: 40
Study 17357764 — intervention group
Group type: COMPARATOR
Intervention: Unacclimatized group (U)
Number of subjects: 40
Study 15159320 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day UDCA for 21 days
Number of subjects: 18
Study 15159320 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day UDCA for 21 days
Number of subjects: 18
Study 15159320 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day UDCA for 21 days
Number of subjects: 18
Study 15159320 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 18
Study 11328958 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infant formula (discharge to 6 mo corrected age)
Number of subjects: 100
Study 11328958 — intervention group
Group type: COMPARATOR
Intervention: Term formula (discharge to 6 mo)
Number of subjects: 100
Study 9572636 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 IU s.c.)
Number of subjects: 11
Study 9572636 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (1 cc s.c.)
Number of subjects: 11
Study 8147095 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) 7.5 micrograms/0.25 ml
Number of subjects: 43
Study 8147095 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) 22.5 micrograms/0.25 ml
Number of subjects: 43
Study 8147095 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) 67.5 micrograms/0.25 ml
Number of subjects: 43
Study 8147095 — intervention group
Group type: COMPARATOR
Intervention: Standard split product vaccine (ST) 22.5 micrograms/ml
Number of subjects: 43
Study 8147095 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified hemagglutinin antigen (HA) highest dose
Number of subjects: 43
Study 8147095 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 43
Study 8147095 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalent dose of HA vaccine
Number of subjects: 43
Study 3048914 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine cream 1 percent
Number of subjects: 60
Study 3048914 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study 31343950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1, 45 minute, in-person intervention focused on transfers skills and seated postural control
Number of subjects: 18
Study 29329957 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB-301 (1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 50 mg/kg)
Number of subjects: 38
Study 29329957 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 38
Study 29329957 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB-301 (50 mg/kg)
Number of subjects: 38
Study 28498195 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE implementation research activities
Number of subjects: 3400
Study 26149465 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 40,000 U subcutaneously once weekly
Number of subjects: 239
Study 26149465 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 80,000 U every 3 weeks
Number of subjects: 239
Study 26149465 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 120,000 U every 3 weeks
Number of subjects: 239
Study 26149465 — intervention group
Group type: EXPERIMENTAL
Intervention: DA 500 mcg every 3 weeks
Number of subjects: 239
Study 26149465 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 239
Study 23880655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free Red Bull (SF-RB) containing caffeine (160 mg) and taurine (2000 mg)
Number of subjects: 17
Study 23880655 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine only drink (160 mg)
Number of subjects: 17
Study 23880655 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free caffeine-free placebo (PL)
Number of subjects: 17
Study 20608874 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 gp120 vaccine
Number of subjects: 0
Study 18534501 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision surgery (MIS) group
Number of subjects: 20
Study 18534501 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 20
Study 18534501 — intervention group
Group type: COMPARATOR
Intervention: Control (skin blood flow over the anterior superior iliac spine)
Number of subjects: 20
Study 16467544 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cetuximab
Number of subjects: 424
Study 16467544 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 424
Study 12780402 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate/latanoprost fixed combination (TLFC) given once each evening
Number of subjects: 32
Study 12780402 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine and timolol solution given twice daily
Number of subjects: 32
Study 11273139 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric distention
Number of subjects: 15
Study 11273139 — intervention group
Group type: COMPARATOR
Intervention: Esophageal distention
Number of subjects: 15
Study 9359537 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (aggressive lipid-lowering therapy)
Number of subjects: 341
Study 9359537 — intervention group
Group type: COMPARATOR
Intervention: Catheter-based revascularization and conventional care (including lipid-lowering therapy if prescribed)
Number of subjects: 341
Study 8239105 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of albuterol (10 mg nebulized in 70 mL over two hours)
Number of subjects: 99
Study 8239105 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulization of albuterol (2.5 mg at 30, 60, 90, and 120 minutes after initial treatment)
Number of subjects: 99
Study 4027764 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly before anaesthesia (neonates)
Number of subjects: 47
Study 4027764 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg X kg‐1 of alpha‐tocopheryl acetate orally for three days before anaesthesia (Group 2 infants)
Number of subjects: 47
Study 4027764 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg X kg‐1 of alpha‐tocopheryl acetate intramuscularly three hours before anaesthesia (Group 3 infants)
Number of subjects: 47
Study 4027764 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E (Group 1 infants)
Number of subjects: 47
Study 4027764 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E (neonates)
Number of subjects: 47
Study 4027764 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E (children)
Number of subjects: 47
Study 29865227 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferulic acid (1000 mg daily)
Number of subjects: 48
Study 26566754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin 300 mg
Number of subjects: 100
Study 26566754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24836866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every month for the first 3 months, followed by every 2 months
Number of subjects: 26
Study 22349989 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208 100 mg bid for 24 weeks
Number of subjects: 482
Study 22349989 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208 100 mg bid for 26 weeks
Number of subjects: 482
Study 22349989 — intervention group
Group type: EXPERIMENTAL
Intervention: RVX-208
Number of subjects: 482
Study 22349989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 20094973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Number of subjects: 20
Study 20094973 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 20
Study 20094973 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (2 hours prior to exercise)
Number of subjects: 20
Study 20094973 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 20
Study 18657831 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% phenylephrine drops
Number of subjects: 41
Study 18657831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15797313 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSS group (n=9)
Number of subjects: 26
Study 15797313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer mothers without PTSS (n=7)
Number of subjects: 26
Study 15797313 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26